Perspective Therapeutics ... (CATX)
2.42
0.09 (3.86%)
At close: Apr 24, 2025, 3:59 PM
2.43
0.41%
After-hours: Apr 24, 2025, 04:05 PM EDT
3.86% (1D)
| Bid | 2.28 |
| Market Cap | 179.21M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -79.28M |
| EPS (ttm) | -1.22 |
| PE Ratio (ttm) | -1.98 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.49 |
| Volume | 1,175,507 |
| Avg. Volume (20D) | 743,408 |
| Open | 2.30 |
| Previous Close | 2.33 |
| Day's Range | 2.28 - 2.44 |
| 52-Week Range | 1.60 - 19.10 |
| Beta | 1.21 |
About CATX
Perspective Therapeutics, Inc., together with its subsidiaries, develops, manufactures, sells, and markets isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company offers CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers. It sells its products to facil...
Industry Medical - Devices
Sector Healthcare
IPO Date Nov 10, 2005
Employees 138
Stock Exchange AMEX
Ticker Symbol CATX
Analyst Forecast
According to 10 analyst ratings, the average rating for CATX stock is "Buy." The 12-month stock price forecast is $15, which is an increase of 519.81% from the latest price.
Stock ForecastsNext Earnings Release
Perspective Therapeutics Inc. is scheduled to release its earnings on May 12, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 months ago
-51.38%
Perspective Therapeutics shares are trading lower....
Unlock content with
Pro Subscription
8 months ago
+0.58%
Perspective Therapeutics shares are trading lower. The company reported Q2 financial results.
